Folate Homeostasis in Cerebrospinal Fluid During Therapy for Acute Lymphoblastic Leukemia

Pediatric Neurology

Volumn 40, Issue 1, 2009, Pages 34-41

  Cole, Peter D ^a   Beckwith, Katherine A ^b   Vijayanathan, Veena ^a   Roychowdhury, Sudipta ^c   Smith, Angela K ^b   Kamen, Barton A ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; CYTARABINE; FOLIC ACID; HOMOCYSTEINE; HYDROCORTISONE; METHOTREXATE; TAU PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID; CHILD; COGNITION; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLIC ACID BLOOD LEVEL; HOMEOSTASIS; HUMAN; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; AMINOPTERIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COGNITION; DEMENTIA, VASCULAR; FOLIC ACID; FOLIC ACID ANTAGONISTS; HOMEOSTASIS; HOMOCYSTEINE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; METHOTREXATE; NEUROTOXICITY SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; TAU PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 57049127093     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.09.005     Document Type: Article

References (48)

1. Lo Nigro L., Di Cataldo A., and Schiliro G. Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Med Pediatr Oncol 35 (2000) 449-455
2. Langer T., Martus P., Ottensmeier H., Hertzberg H., Beck J.D., and Meier W. CNS late-effects after ALL therapy in childhood. Part III: Neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol 38 (2002) 320-328
3. Mulhern R.K., and Butler R.W. Neurocognitive sequelae of childhood cancers and their treatment. Pediatr Rehabil 7 (2004) 1-14 discussion 15-6
4. Iuvone L., Mariotti P., Colosimo C., Guzzetta F., Ruggiero A., and Riccardi R. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer 95 (2002) 2562-2570
5. Mulhern R.K., Fairclough D., and Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. [Erratum in: J Clin Oncol 1991;9:1922]. J Clin Oncol 9 (1991) 1348-1356
6. Copeland D.R., Moore III B.D., Francis D.J., Jaffe N., and Culbert S.J. Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study. J Clin Oncol 14 (1996) 2826-2835
7. Schagen S.B., Vardy J., Schagen S.B., and Vardy J. Steering Committee of the International Cognition and Cancer Task Force. Cognitive dysfunction in people with cancer. Lancet Oncol 8 (2007) 852-853
8. Mody R., Li S., Dover D.C., et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 111 (2008) 5515-5523
9. Waber D.P., Gioia G., Paccia J., et al. Sex differences in cognitive processing in children treated with CNS prophylaxis for acute lymphoblastic leukemia. J Pediatr Psychol 15 (1990) 105-122
10. Robison L.L., Nesbit Jr. M.E., Sather H.N., Meadows A.T., Ortega J.A., and Hammond G.D. Factors associated with IQ scores in long-term survivors of childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 6 (1984) 115-121
11. Anderson V.A., Godber T., Smibert E., Weiskop S., and Ekert H. Cognitive and academic outcome following cranial irradiation and chemotherapy in children: a longitudinal study. Br J Cancer 82 (2000) 255-262
12. Jankovic M., Brouwers P., Valsecchi M.G., and ISPACC: International Study Group on Psychosocial Aspects of Childhood Cancer. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. Lancet 344 (1994) 224-227
13. Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 15 (2000) 603-630
14. Montour-Proulx I., Kuehn S.M., Keene D.L., et al. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 20 (2005) 129-133
15. Pääkkö E., Harila-Saari A., Vanionpää L., Himanen S., Pyhtinen J., and Lanning M. White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings. Med Pediatr Oncol 35 (2000) 456-461
16. Cole P.D., and Kamen B.A. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev 12 (2006) 174-183
17. Quinn C.T., and Kamen B.A. A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 44 (1996) 522-530
18. Hesse C., Rosengren L., Andreasen N., et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297 (2001) 187-190
19. Maruyama M., Matsui T., Tanji H., et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 61 (2004) 716-720
20. Shoji M., Matsubara E., Murakami T., et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging 23 (2002) 363-370
21. Van Gool S.W., De Meyer G., Van de Voorde A., Vanmechelen E., and Vanderstichele H. Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology 25 (2004) 471-480
22. Muszyńska-Rosłan K., Krawczuk-Rybak M., Protas P.T., and Hołownia A. Level of tau protein in children treated for acute lymphoblastic leukemia. Pediatr Neurol 34 (2006) 367-371
23. Holownia A., Trofimiuk E., Krawczuk-Rybak M., et al. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol. Acta Haematol 112 (2004) 222-224
24. Cole P.D., Zebala J.A., Alcaraz M.J., Smith A.K., Tan J., and Kamen B.A. Pharmacodynamic properties of methotrexate and aminotrexate during weekly therapy. Cancer Chemother Pharmacol 57 (2006) 826-834
25. Cole P.D., Drachtman R.A., Masterson M., et al. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 62 (2008) 65-75
26. Kamen B.A., Takach P.L., Vatev R., and Caston J.D. A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 70 (1976) 54-63
27. Pfeiffer C.M., Huff D.L., and Gunter E.W. Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem 45 (1999) 290-292
28. Jansen N.C., Kingma A., Tellegen P., et al. Feasibility of neuropsychological assessment in leukaemia patients shortly after diagnosis: directions for future prospective research. Arch Dis Child 90 (2005) 301-304
29. BCSH General Haematology Task Force. Guidelines on the investigation and diagnosis of cobalamin and folate deficiencies: a publication of the British Committee for Standards in Haematology. Clin Lab Haematol 16 (1994) 101-115
30. Valik D., Radina M., Sterba J., and Vojtesek B. Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy. Pharmacogenomics 5 (2004) 1151-1162
31. Lipton S.A., Kim W.K., Choi Y.B., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci U S A 94 (1997) 5923-5928
32. Reynolds E.H., Gallagher B.B., Mattson R.H., Bowers M., and Johnson A.L. Relationship between serum and cerebrospinal fluid folate. Nature 240 (1972) 155-157
33. 12 are related in blood and cerebrospinal fluid. Clin Chem 53 (2007) 326-333
34. McIntosh S., Klatskin E.H., O'Brien R.T., et al. Chronic neurologic disturbance in childhood leukemia. Cancer 37 (1976) 853-857
35. Orr R.B., and Kamen B.A. Identification of a point mutation in the folate receptor gene that confers a dominant negative phenotype. Cancer Res 55 (1995) 847-852
36. Tran T., Shatnawi A., Zheng X., Kelley K.M., and Ratnam M. Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Res 65 (2005) 4431-4441
37. Kruse T., Reiber H., and Neuhoff V. Amino acid transport across the human blood-CSF barrier: an evaluation graph for amino acid concentrations in cerebrospinal fluid. J Neurol Sci 70 (1985) 129-138
38. McKeever M.P., Weir D.G., Molloy A., and Scott J.M. Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci (Lond) 81 (1991) 551-556
39. Quinn C.T., Griener J.C., Bottiglieri T., Arning E., and Winick N.J. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. J Pediatr Hematol Oncol 26 (2004) 386-388
40. Cole P.D., Drachtman R.A., Smith A.K., et al. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res 11 (2005) 8089-8096
41. Smith A., Hum M., Winick N.J., and Kamen B.A. A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 2 (1996) 69-73
42. Reddick W.E., Glass J.O., Helton K.J., et al. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. Am J Neuroradiol 26 (2005) 1263-1269
43. Mahoney Jr. D.H., Shuster J., Nitschke R., et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol 16 (1998) 246-254
44. Bleyer W.A., and Dedrick R.L. Clinical pharmacology of intrathecal methotrexate: I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61 (1977) 703-708
45. Surtees R., Leonard J., and Austin S. Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 338 (1991) 1550-1554
46. Kishi T., Tanaka Y., and Ueda K. Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer 89 (2000) 925-931
47. (1-42) in cerebrospinal fluid. Clin Chem 53 (2007) 1129-1136
48. Vafai S.B., and Stock J.B. Protein phosphatase 2a methylation: a link between elevated plasma homocysteine and Alzheimer's disease. FEBS Lett 518 (2002) 1-4